Effective January 1, 2014, IBC will use a single precertification requirement list across all managed care products. This change is being made as we continue to look for ways to improve and simplify the precertification process. Significant changes will be made to the precertification requirements for the following three categories effective January 1, 2014: Outpatient surgical procedures. For standard HMO products, not all outpatient surgical procedures will require precertification. Only select outpatient surgical procedures will be included on the precertification requirement list. Durable medical equipment (DME) and prosthetic items. Currently, precertification is required for all rentals and purchases of DME and prosthetic items that cost more than $500. Effective January 1, 2014, only certain DME and prosthetic items will require precertification, regardless of the cost of these items. Injectable and infusion therapy drugs. Precertification requirements will be added for Acthar H.P.^®, Adcetris^®, Kyprolis^®, Naglazyme^®, Perjeta^®, Simponi^® Aria, Veletri^®, and Xofigo^®. Precertification approval will no longer be required for Lucentis^®, Macugen^®, Mozobil^®, and Temodar^®. In addition, precertification requirements for 23 drugs will be removed for members who have Flex products. The drugs include Aranesp^®, Neulasta^®, and Eligard^®. These changes are reflected on the precertification requirement list available on our Preapproval/Precertification for Services web page. If you have any questions, please contact Cheryl McGurk, Manager of Precertification, at 215-241-4542.